Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia

Scandinavian Journal of Urology

Volumn 47, Issue 5, 2013, Pages 384-389

  Inci, Mehmet ^a   Sarli, Bahadir ^b   Davarci, Mursel ^a   Yalcinkaya, Fatih Rustu ^a   Rifaioǧlu, Murat Mehmet ^a   Davran, Ramazan ^a   Arica, Secil ^a   Motor, Sedat ^a   Demirbaş, Onur ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Kayseri Education and Research Hospital ^*  (Turkey)

Author keywords

Benign prostatic hyperplasia; Blood pressure variability; Endothelial dysfunction; Nocturia

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; QUESTIONNAIRE;

ADULT; AGED; BRACHIAL ARTERY; CASE-CONTROL STUDIES; COMORBIDITY; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MIDDLE AGED; NOCTURIA; ORGAN SIZE; PROSTATE; PROSTATIC HYPERPLASIA; REGIONAL BLOOD FLOW; RISK FACTORS;

EID: 84885413093     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2012.762038     Document Type: Article

References (32)

1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359-67.
2. Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 2011;6:161-72.
3. Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br J Urol 1982;54: 252-5.
4. Agarwal R, Light RP, Bills JE, Hummel LA. Nocturia, nocturnal activity, and nondipping. Hypertension 2009;54: 646-51.
5. Lee YJ, Jeong SJ, Byun SS, Lee JJ, Han JW, Kim KW. Prevalence and correlates of nocturia in community-dwelling older men: results from the Korean longitudinal study on health and aging. Korean J Urol 2012;53:263-7.
6. Fiske J, Scarpero HM, Xue X, Nitti VW. Degree of bother caused by nocturia in women. Neurourol Urodyn 2004;23: 130-3.
7. Yu HJ, Chen FY, Huang PC, Chen TH, Chie WC, Liu CY. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology 2006;67:713-18.
8. Asplund R, Johansson S, Henriksson S, Isacsson G. Nocturia, depression and antidepressant medication. BJU Int 2005;95:820-3.
9. Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003;91:190-5.
10. Van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002;90:644-8.
11. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992;10:98-104.
12. Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217-20.
13. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999;84:297-301.
14. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101: 1899-906.
15. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998;82:1535-9; A1537-8.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34:62-9.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-52.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
19. Turgut F, Bayrak O, Kanbay M, Ozkara A, Uz E, Bavbek N, et al. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia. Scand J Urol Nephrol 2008;42:47-52.
20. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405-16.
21. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-3.
22. Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999;21:1732-48.
23. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-8.
24. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hyp-oxia. Prostate 2003;57:57-65.
25. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign pros-tatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007;177:1395-400.
26. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign pros-tatic hyperplasia. Eur Urol 2007;51:199-206.
27. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropo-metric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006;68:1198-205.
28. Garbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010;12:157-80.
29. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44.
30. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98:1038-42.
31. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725-9.
32. Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292-6.